TP

DRUG2 trials

Sponsors

Chinese Academy of Medical Sciences, Hospital of Stomatology, Wuhan University

Conditions

Breast CancerOral Squamous Cell Carcinoma

Phase 2

Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer

CompletedNCT01150513

Chinese Academy of Medical SciencesBreast Cancer

Start: 2009-06-30End: 2016-04-30Updated: 2021-02-09

Phase 3

Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma

RecruitingNCT05798793

Hospital of Stomatology, Wuhan UniversityOral Squamous Cell Carcinoma

Start: 2023-11-21End: 2026-10-01Target: 309Updated: 2024-04-02

Related Papers

Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer

Cancer Biology and Medicine2023-03-0211 citations

Abstract 5084: <i>KMT2D</i> and <i>PIK3CA</i> mutation as potential factors to predict adjuvant chemotherapy efficacy in surgical triple negative breast cancer

Cancer Research2022-06-151 citations

Abstract 5689: Effects of homologous recombination-related gene mutation subtypes on gene instability and the efficacy of platinum-containing regiments in triple-negative breast cancer

Cancer Research2022-06-15

Abstract P1-08-12: The status of homologous recombination deficiency is a potential biomarker for platinum-based chemotherapy in triple-negative breast cancer

Cancer Research2022-02-15

Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up.

2021-10-1411 citations

Efficacy of epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes as adjuvant chemotherapy in triple-negative breast cancer: 8.1 years median follow-up on a randomized clinical trial.

Journal of Clinical Oncology2021-05-20

Comparison of four cycles epirubicin and cyclophosphamide (EC) followed by four cycles docetaxel (T) versus six cycles docetaxel and carboplatin (TP) as adjuvant chemotherapy for women with operable triple negative breast cancer.

Journal of Clinical Oncology2016-05-202 citations